Core Viewpoint - The company, Guo'en Holdings (08121), has announced a placement agreement to issue up to 5 million shares at a price of HKD 0.60 per share, representing an approximate discount of 11.76% from the market price on the agreement date [1] Group 1: Placement Details - The placement will be conducted through a placement agent to no fewer than six independent third-party subscribers [1] - The estimated net proceeds from the placement are approximately HKD 2.7 million [1] Group 2: Use of Proceeds - The company intends to use the net proceeds entirely to support the development of its healthcare business, which includes hiring suitable talent, covering daily expenses of Shandong Guo'en, launching marketing activities, and developing sales platforms [1]

Core Viewpoint - Wu Xi Life (08148) plans to issue up to 25.45 million placement shares, representing approximately 6.3% of the company's enlarged issued share capital after the placement [1] Summary by Category Share Placement Details - The placement price is set at HKD 0.55 per share, which is a discount of approximately 19.12% compared to the closing price of HKD 0.68 on August 21 [1] - If all placement shares are fully subscribed, the net proceeds from the placement will be approximately HKD 13.5 million [1] Use of Proceeds - The company intends to use at least 70% of the net proceeds to expand its product sales business, with the remainder allocated for general working capital [1]

Core Viewpoint - The company, Guoen Holdings (08121), has announced a placement agreement to issue up to 5 million shares at a price of HKD 0.60 per share, representing an approximate discount of 11.76% from the closing price of HKD 0.680 on the date of the agreement [1] Group 1 - The placement is conditional and will be made to no less than six independent third-party investors [1] - The estimated net proceeds from the placement are approximately HKD 2.7 million [1] - The funds raised will be used to support the development of the company's healthcare business, including hiring suitable talent, covering daily expenses of Shandong Guoen, launching marketing activities, and developing sales platforms [1]

Group 1 - The company, Hansoh Pharmaceutical (03692), has entered into a placement agreement to issue 108 million shares at a price of HKD 36.30 per share, representing approximately 1.78% of the enlarged issued share capital post-placement [1] - The placement price of HKD 36.30 is approximately 6.49% lower than the closing price of HKD 38.82 on August 19, 2025 [1] Group 2 - The net proceeds from the placement, after deducting commissions, fees, and transaction costs, are estimated to be approximately HKD 3.897 billion, with a net price per share of about HKD 36.08 [2] - The company plans to allocate approximately 65% of the net proceeds for the research and development of new innovative drugs in areas such as oncology, autoimmune diseases, central nervous system, and metabolic diseases, as well as licensing innovative drugs and technology platforms [2] - Approximately 25% of the proceeds will be used for constructing new innovative drug production facilities and R&D laboratories, and upgrading existing R&D laboratories and production facilities [2] - The remaining 10% will be allocated for working capital and other general corporate purposes [2]

Core Viewpoint - The company, Gilead Sciences-B (01672), has entered into a placement and subscription agreement to sell and issue shares, which will result in a significant change in shareholding structure and raise funds for clinical trials and operational needs [1][2]. Group 1: Share Placement and Subscription Details - The total number of shares to be placed is 52.4 million, representing approximately 5.44% of the company's issued share capital as of the announcement date [2]. - The subscription involves 28.82 million new shares, accounting for about 2.90% of the enlarged issued share capital post-placement and subscription [2]. - The placement price is set at HKD 16.45 per share, which is a discount of approximately 9.9% compared to the closing price of HKD 18.26 on the last trading day [2]. Group 2: Shareholding Changes - Following the completion of the placement and subscription, the selling shareholder's stake will decrease from approximately 53.38% to 49.45% of the issued share capital [2]. - The total shareholding percentage of the controlling shareholder will reduce from about 62.21% to approximately 58.03% after the issuance of the new shares [2]. Group 3: Use of Proceeds - The net proceeds from the subscription are expected to be around HKD 468 million after deducting commissions and estimated expenses [2]. - Approximately 90% of the net proceeds is intended for the development of clinical trials related to subcutaneous and oral peptide candidates for obesity [2]. - The remaining 10% of the net proceeds is suggested for working capital and other general corporate purposes [2].

Core Viewpoint - The company plans to place 5 million shares to TruMed at a price of HKD 20 per share, representing a discount of approximately 10.95% from the market price on August 15, 2025, which was HKD 22.46 [1] Group 1: Fundraising and Financial Impact - The expected net proceeds from the placement are approximately HKD 99 million [1] - About 60% of the net proceeds will be used to repay existing interest-bearing bank loans, which have increased due to additional borrowing for R&D expenses, leading to a rise in the company's debt-to-asset ratio [1] - The repayment of these loans is anticipated to strengthen the company's financial position, reduce interest-bearing debt ratio, and lower financial expenses [1] Group 2: Allocation of Proceeds - Approximately 30% of the net proceeds will be allocated for the development of new pipelines, including QX027N, QX031N, and QX035N [1] - About 10% of the proceeds will be used for working capital and other corporate purposes [1] Group 3: Investor Profile - TruMed is a fund primarily investing in healthcare stocks, controlled by Ting WANG [1]

Group 1 - The company approved a cash increase of up to RMB 300 million to participate in the financing of Shanghai Haihe Pharmaceutical Research and Development Co., Ltd. [1][2] - The company plans to acquire no less than 5% and no more than 8.09% of the equity in Haihe Pharmaceutical after the financing is completed [1][2] - The company will subscribe to a maximum of 63.157895 million new shares at a price of RMB 4.75 per share [1][2] Group 2 - The company will sign a subscription agreement with Haihe Pharmaceutical and related parties, which requires approval from the shareholders' meeting [2] - The board of directors and management are authorized to sign supplementary agreements regarding specific subscription amounts and quantities after the subscription agreement takes effect [2]

昊天国际建投(01341)公布，于2025年8月7日，该公司拟透过配售代理配售合共最多2亿股配售股份，配 售价格为每股港币0.20元，较配售协议日期联交所所报股份收市价每股港币0.208元折让约3.85%。 假设所有配售股份均获悉数配售，净筹约3940万港元，拟用作集团的一般营运资金。 ...

消息面上，近日，LFG投资控股公布，配售最多8119万股新股，占公司经扩大股本16.67%；配售价0.4 港元。集资总额3250万港元，所得净额3230万港元，拟用于增加资本基础以拓扩证券融资业务及用作集 团的一般营运资金。值得注意的是，香港联交所最新资料显示，7月25日，LFG投资控股股东将股票存 入力高证券，存仓市值759.94万港元，占比5.13%。 智通财经APP获悉，LFG投资控股(03938)再涨超28%，值得注意的是，该股近期接连攀升，月内股价已 飙升4.5倍。截至发稿，涨28.33%，报0.77港元，成交额1686.91万港元。 ...

消息面上，同源康医药-B发布公告，于2025年7月28日，公司与配售代理订立配售协议，据此，配售代 理有条件同意作为公司的配售代理，按尽力基准促使承配人按每股配售股份17.01港元的配售价购买923 万股配售股份。 同源康医药-B(02410)涨超3%，截至发稿，涨2.34%，报21.85港元，成交额3234.21万港元。 假设所有配售股份获悉数配售及待完成后，预期配售事项所得款项总额及所得款项净额(经扣除配售佣 金及配售事项的其他相关成本及开支后)将分别约为1.57亿港元及1.55亿港元。按此基准，净发行价将约 为每股股份16.76港元。公司拟按如下方式分配配售事项所得款项净额(经扣除发行费用后)：配售事项所 得款项净额的约60%，用于现有管线的研发及商业化；配售事项所得款项净额的约30%，用于加强其内 部研发技术能力及扩展其产品组合；及配售事项所得款项净额的约10%，用于营运资金及一般企业用 途。 假设于本公告日期至交割日期期间已发行股份数目并无变动，则配售事项项下的923万股配售股份相当 于经配发及发行配售股份扩大后的已发行H股数目的约2.46%及已发行股份数目的约2.43%。每股配售股 份17.01港 ...